alpha-Glucosidase Inhibitor Screening Kit (Colorimetric) (ab284520)
Key features and details
- Assay type: Enzyme activity (quantitative)
- Detection method: Colorimetric
- Platform: Microplate (12 x 8 well strips)
- Sample type: Inhibitor compounds
Overview
-
Product name
alpha-Glucosidase Inhibitor Screening Kit (Colorimetric)
See all GAA kits -
Detection method
Colorimetric -
Sample type
Inhibitor compounds -
Assay type
Enzyme activity (quantitative) -
Assay duration
Multiple steps standard assay -
Product overview
The α-Glucosidase Inhibitor Screening Kit (ab284520) (K938) can be used to screen potential inhibitors of this enzyme. It utilizes the ability of an active α-Glucosidase to cleave a synthetic substrate thus, releasing a chromophore (OD: 410 nm). In the presence of an α-Glucosidase specific inhibitor, the enzymatic activity is greatly reduced which is detected by a decrease of absorbance readings.
The assay kit provides a rapid, simple and reliable test for high-throughput screening of α-Glucosidase inhibitors.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called K938 a-Glucosidase Inhibitor Screening Kit (Colorimetric). K938-100 is the same size as the 100 test size of ab284520.
-
Platform
Microplate (12 x 8 well strips)
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components Identifier 100 tests Acarbose Red 1 x 140µl alpha-Glucosidase Blue 1 vial alpha-Glucosidase Assay Buffer WM 1 x 25ml alpha-Glucosidase Substrate Mix Amber 1 x 300µl -
Research areas
-
Function
Essential for the degradation of glygogen to glucose in lysosomes. -
Involvement in disease
Defects in GAA are the cause of glycogen storage disease type 2 (GSD2) [MIM:232300]; also called acid alpha-glucosidase (GAA) deficiency or acid maltase deficiency (AMD). GSD2 is a metabolic disorder with a broad clinical spectrum. The severe infantile form, or Pompe disease, presents at birth with massive accumulation of glycogen in muscle, heart and liver. Cardiomyopathy and muscular hypotonia are the cardinal features of this form whose life expectancy is less than two years. The juvenile and adult forms present as limb-girdle muscular dystrophy beginning in the lower limbs. Final outcome depends on respiratory muscle failure. Patients with the adult form can be free of clinical symptoms for most of their life but finally develop a slowly progressive myopathy. -
Sequence similarities
Belongs to the glycosyl hydrolase 31 family.
Contains 1 P-type (trefoil) domain. -
Post-translational
modificationsThe different forms of acid glucosidase are obtained by proteolytic processing.
Phosphorylation of mannose residues ensures efficient transport of the enzyme to the lysosomes via the mannose 6-phosphate receptor. -
Cellular localization
Lysosome. Lysosome membrane. - Information by UniProt
-
Alternative names
- 70 kDa lysosomal alpha-glucosidase
- Acid alpha glucosidase
- Acid maltase
see all
Images
-
Inhibition of alpa-Glucosidase activity by Acarbose
α-Glucosidase activity inhibition by Acarbose. IC50 of Acarbose was calculated to be 0.74 ± 0.15 mM. Assay was carried out following the kit protocol.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab284520 has not yet been referenced specifically in any publications.